European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C

Author (Corporate)
Series Title
Series Details 21.02.14
Publication Date 21/02/2014
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave in February 2014 an opinion on the use of a fixed-dose combination of ledipasvir and sofosbuvir in the treatment of chronic (long-term) hepatitis C virus (HCV) infection in a compassionate-use programme.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/02/news_detail_002032.jsp&mid=WC0b01ac058004d5c1
Subject Categories
Countries / Regions